GenSight Biologics has completed a fundraising round totalling €3,694,665.92, through subscriptions by its three existing shareholders — Heights Capital, Invus and Alumni Capital — using the same share-plus-warrant structure as its July private placement.
The company said it will use up to 75 % of the net proceeds to advance its lead gene therapy candidate, GS010/LUMEVOQ, including finalizing manufacturing transfer and preparing for a French early access programme and its Phase III RECOVER trial. The remainder will go toward existing obligations, including redemption of convertible bonds.
Prior to this capital raise, GenSight’s cash and cash equivalents stood at about €1.0 million, and its total debt was approximately €26.1 million (nominal and interest, undiscounted). With the new funds, the company expects its cash runway to extend from mid-October 2025 to late Q4 2025. The company noted that if its planned early access programme in France is delayed, additional financing may be needed before the end of 2025.
Under the fundraising terms, GenSight issued 18,816,666 ordinary shares, 13,060,600 pre-funded warrants, and 31,877,266 investor warrants. If all warrants are exercised over their 58-month term, an additional €6,824,831.86 could be generated. The new shares are expected to begin trading on Euronext Paris from September 30, 2025.
GenSight’s current operational plan includes seeking alternative funding options—such as licensing, partnerships, or non-dilutive sources—while preparing for its global Phase III trial and marketing authorisation submission efforts.
